The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Heart Failure Therapeutics Market Research Report 2025
Synopsis
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.
The global Heart Failure Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Heart Failure Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heart Failure Therapeutics.
Report Scope
The Heart Failure Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Heart Failure Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heart Failure Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates
Segment by Type
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm
Segment by Application
Hospital
Clinic
Medical Research Organization
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Heart Failure Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.
The global Heart Failure Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Heart Failure Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heart Failure Therapeutics.
Report Scope
The Heart Failure Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Heart Failure Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Heart Failure Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates
Segment by Type
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm
Segment by Application
Hospital
Clinic
Medical Research Organization
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Heart Failure Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Heart Failure Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diagnosis
1.2.3 Prognosis
1.2.4 Treatment Options and Treatment Algorithm
1.3 Market by Application
1.3.1 Global Heart Failure Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Medical Research Organization
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Heart Failure Therapeutics Market Perspective (2019-2030)
2.2 Heart Failure Therapeutics Growth Trends by Region
2.2.1 Global Heart Failure Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Heart Failure Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Heart Failure Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Heart Failure Therapeutics Market Dynamics
2.3.1 Heart Failure Therapeutics Industry Trends
2.3.2 Heart Failure Therapeutics Market Drivers
2.3.3 Heart Failure Therapeutics Market Challenges
2.3.4 Heart Failure Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Heart Failure Therapeutics Players by Revenue
3.1.1 Global Top Heart Failure Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Heart Failure Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Heart Failure Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Heart Failure Therapeutics Revenue
3.4 Global Heart Failure Therapeutics Market Concentration Ratio
3.4.1 Global Heart Failure Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Heart Failure Therapeutics Revenue in 2023
3.5 Heart Failure Therapeutics Key Players Head office and Area Served
3.6 Key Players Heart Failure Therapeutics Product Solution and Service
3.7 Date of Enter into Heart Failure Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Heart Failure Therapeutics Breakdown Data by Type
4.1 Global Heart Failure Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Heart Failure Therapeutics Forecasted Market Size by Type (2025-2030)
5 Heart Failure Therapeutics Breakdown Data by Application
5.1 Global Heart Failure Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Heart Failure Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Heart Failure Therapeutics Market Size (2019-2030)
6.2 North America Heart Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Heart Failure Therapeutics Market Size by Country (2019-2024)
6.4 North America Heart Failure Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Heart Failure Therapeutics Market Size (2019-2030)
7.2 Europe Heart Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Heart Failure Therapeutics Market Size by Country (2019-2024)
7.4 Europe Heart Failure Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Heart Failure Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Heart Failure Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Heart Failure Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Heart Failure Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Heart Failure Therapeutics Market Size (2019-2030)
9.2 Latin America Heart Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Heart Failure Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Heart Failure Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Heart Failure Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Heart Failure Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Heart Failure Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Heart Failure Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Heart Failure Therapeutics Introduction
11.1.4 Bayer Revenue in Heart Failure Therapeutics Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 Cynokinetics
11.2.1 Cynokinetics Company Detail
11.2.2 Cynokinetics Business Overview
11.2.3 Cynokinetics Heart Failure Therapeutics Introduction
11.2.4 Cynokinetics Revenue in Heart Failure Therapeutics Business (2019-2024)
11.2.5 Cynokinetics Recent Development
11.3 Les Laboratoires Servier
11.3.1 Les Laboratoires Servier Company Detail
11.3.2 Les Laboratoires Servier Business Overview
11.3.3 Les Laboratoires Servier Heart Failure Therapeutics Introduction
11.3.4 Les Laboratoires Servier Revenue in Heart Failure Therapeutics Business (2019-2024)
11.3.5 Les Laboratoires Servier Recent Development
11.4 Merck & Co.
11.4.1 Merck & Co. Company Detail
11.4.2 Merck & Co. Business Overview
11.4.3 Merck & Co. Heart Failure Therapeutics Introduction
11.4.4 Merck & Co. Revenue in Heart Failure Therapeutics Business (2019-2024)
11.4.5 Merck & Co. Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Heart Failure Therapeutics Introduction
11.5.4 Novartis Revenue in Heart Failure Therapeutics Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Procoralan
11.6.1 Procoralan Company Detail
11.6.2 Procoralan Business Overview
11.6.3 Procoralan Heart Failure Therapeutics Introduction
11.6.4 Procoralan Revenue in Heart Failure Therapeutics Business (2019-2024)
11.6.5 Procoralan Recent Development
11.7 Bristol-Myers Squibb Company
11.7.1 Bristol-Myers Squibb Company Company Detail
11.7.2 Bristol-Myers Squibb Company Business Overview
11.7.3 Bristol-Myers Squibb Company Heart Failure Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Company Revenue in Heart Failure Therapeutics Business (2019-2024)
11.7.5 Bristol-Myers Squibb Company Recent Development
11.8 Cardiorentis AG
11.8.1 Cardiorentis AG Company Detail
11.8.2 Cardiorentis AG Business Overview
11.8.3 Cardiorentis AG Heart Failure Therapeutics Introduction
11.8.4 Cardiorentis AG Revenue in Heart Failure Therapeutics Business (2019-2024)
11.8.5 Cardiorentis AG Recent Development
11.9 CVie Therapeutics Limited
11.9.1 CVie Therapeutics Limited Company Detail
11.9.2 CVie Therapeutics Limited Business Overview
11.9.3 CVie Therapeutics Limited Heart Failure Therapeutics Introduction
11.9.4 CVie Therapeutics Limited Revenue in Heart Failure Therapeutics Business (2019-2024)
11.9.5 CVie Therapeutics Limited Recent Development
11.10 Orion Corporation
11.10.1 Orion Corporation Company Detail
11.10.2 Orion Corporation Business Overview
11.10.3 Orion Corporation Heart Failure Therapeutics Introduction
11.10.4 Orion Corporation Revenue in Heart Failure Therapeutics Business (2019-2024)
11.10.5 Orion Corporation Recent Development
11.11 PhaseBio Pharmaceuticals
11.11.1 PhaseBio Pharmaceuticals Company Detail
11.11.2 PhaseBio Pharmaceuticals Business Overview
11.11.3 PhaseBio Pharmaceuticals Heart Failure Therapeutics Introduction
11.11.4 PhaseBio Pharmaceuticals Revenue in Heart Failure Therapeutics Business (2019-2024)
11.11.5 PhaseBio Pharmaceuticals Recent Development
11.12 Market Segment by Product Type
11.12.1 Market Segment by Product Type Company Detail
11.12.2 Market Segment by Product Type Business Overview
11.12.3 Market Segment by Product Type Heart Failure Therapeutics Introduction
11.12.4 Market Segment by Product Type Revenue in Heart Failure Therapeutics Business (2019-2024)
11.12.5 Market Segment by Product Type Recent Development
11.13 B-Blockers
11.13.1 B-Blockers Company Detail
11.13.2 B-Blockers Business Overview
11.13.3 B-Blockers Heart Failure Therapeutics Introduction
11.13.4 B-Blockers Revenue in Heart Failure Therapeutics Business (2019-2024)
11.13.5 B-Blockers Recent Development
11.14 Calcium Channel Blockers
11.14.1 Calcium Channel Blockers Company Detail
11.14.2 Calcium Channel Blockers Business Overview
11.14.3 Calcium Channel Blockers Heart Failure Therapeutics Introduction
11.14.4 Calcium Channel Blockers Revenue in Heart Failure Therapeutics Business (2019-2024)
11.14.5 Calcium Channel Blockers Recent Development
11.15 Cardiac Glycosides
11.15.1 Cardiac Glycosides Company Detail
11.15.2 Cardiac Glycosides Business Overview
11.15.3 Cardiac Glycosides Heart Failure Therapeutics Introduction
11.15.4 Cardiac Glycosides Revenue in Heart Failure Therapeutics Business (2019-2024)
11.15.5 Cardiac Glycosides Recent Development
11.16 Diuretics
11.16.1 Diuretics Company Detail
11.16.2 Diuretics Business Overview
11.16.3 Diuretics Heart Failure Therapeutics Introduction
11.16.4 Diuretics Revenue in Heart Failure Therapeutics Business (2019-2024)
11.16.5 Diuretics Recent Development
11.17 Morphine
11.17.1 Morphine Company Detail
11.17.2 Morphine Business Overview
11.17.3 Morphine Heart Failure Therapeutics Introduction
11.17.4 Morphine Revenue in Heart Failure Therapeutics Business (2019-2024)
11.17.5 Morphine Recent Development
11.18 Vasodilators/Nitrates
11.18.1 Vasodilators/Nitrates Company Detail
11.18.2 Vasodilators/Nitrates Business Overview
11.18.3 Vasodilators/Nitrates Heart Failure Therapeutics Introduction
11.18.4 Vasodilators/Nitrates Revenue in Heart Failure Therapeutics Business (2019-2024)
11.18.5 Vasodilators/Nitrates Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Heart Failure Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Diagnosis
Table 3. Key Players of Prognosis
Table 4. Key Players of Treatment Options and Treatment Algorithm
Table 5. Global Heart Failure Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Heart Failure Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Heart Failure Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Heart Failure Therapeutics Market Share by Region (2019-2024)
Table 9. Global Heart Failure Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Heart Failure Therapeutics Market Share by Region (2025-2030)
Table 11. Heart Failure Therapeutics Market Trends
Table 12. Heart Failure Therapeutics Market Drivers
Table 13. Heart Failure Therapeutics Market Challenges
Table 14. Heart Failure Therapeutics Market Restraints
Table 15. Global Heart Failure Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Heart Failure Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Heart Failure Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heart Failure Therapeutics as of 2023)
Table 18. Ranking of Global Top Heart Failure Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Heart Failure Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Heart Failure Therapeutics Product Solution and Service
Table 22. Date of Enter into Heart Failure Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Heart Failure Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Heart Failure Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Heart Failure Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Heart Failure Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Heart Failure Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Heart Failure Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Heart Failure Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Heart Failure Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Heart Failure Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Heart Failure Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Heart Failure Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Heart Failure Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Heart Failure Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Heart Failure Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Heart Failure Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Heart Failure Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Heart Failure Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Heart Failure Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Heart Failure Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Heart Failure Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Heart Failure Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Heart Failure Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Heart Failure Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Bayer Company Detail
Table 48. Bayer Business Overview
Table 49. Bayer Heart Failure Therapeutics Product
Table 50. Bayer Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Bayer Recent Development
Table 52. Cynokinetics Company Detail
Table 53. Cynokinetics Business Overview
Table 54. Cynokinetics Heart Failure Therapeutics Product
Table 55. Cynokinetics Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Cynokinetics Recent Development
Table 57. Les Laboratoires Servier Company Detail
Table 58. Les Laboratoires Servier Business Overview
Table 59. Les Laboratoires Servier Heart Failure Therapeutics Product
Table 60. Les Laboratoires Servier Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Les Laboratoires Servier Recent Development
Table 62. Merck & Co. Company Detail
Table 63. Merck & Co. Business Overview
Table 64. Merck & Co. Heart Failure Therapeutics Product
Table 65. Merck & Co. Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 66. Merck & Co. Recent Development
Table 67. Novartis Company Detail
Table 68. Novartis Business Overview
Table 69. Novartis Heart Failure Therapeutics Product
Table 70. Novartis Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Procoralan Company Detail
Table 73. Procoralan Business Overview
Table 74. Procoralan Heart Failure Therapeutics Product
Table 75. Procoralan Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Procoralan Recent Development
Table 77. Bristol-Myers Squibb Company Company Detail
Table 78. Bristol-Myers Squibb Company Business Overview
Table 79. Bristol-Myers Squibb Company Heart Failure Therapeutics Product
Table 80. Bristol-Myers Squibb Company Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Bristol-Myers Squibb Company Recent Development
Table 82. Cardiorentis AG Company Detail
Table 83. Cardiorentis AG Business Overview
Table 84. Cardiorentis AG Heart Failure Therapeutics Product
Table 85. Cardiorentis AG Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 86. Cardiorentis AG Recent Development
Table 87. CVie Therapeutics Limited Company Detail
Table 88. CVie Therapeutics Limited Business Overview
Table 89. CVie Therapeutics Limited Heart Failure Therapeutics Product
Table 90. CVie Therapeutics Limited Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 91. CVie Therapeutics Limited Recent Development
Table 92. Orion Corporation Company Detail
Table 93. Orion Corporation Business Overview
Table 94. Orion Corporation Heart Failure Therapeutics Product
Table 95. Orion Corporation Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Orion Corporation Recent Development
Table 97. PhaseBio Pharmaceuticals Company Detail
Table 98. PhaseBio Pharmaceuticals Business Overview
Table 99. PhaseBio Pharmaceuticals Heart Failure Therapeutics Product
Table 100. PhaseBio Pharmaceuticals Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 101. PhaseBio Pharmaceuticals Recent Development
Table 102. Market Segment by Product Type Company Detail
Table 103. Market Segment by Product Type Business Overview
Table 104. Market Segment by Product Type Heart Failure Therapeutics Product
Table 105. Market Segment by Product Type Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 106. Market Segment by Product Type Recent Development
Table 107. B-Blockers Company Detail
Table 108. B-Blockers Business Overview
Table 109. B-Blockers Heart Failure Therapeutics Product
Table 110. B-Blockers Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 111. B-Blockers Recent Development
Table 112. Calcium Channel Blockers Company Detail
Table 113. Calcium Channel Blockers Business Overview
Table 114. Calcium Channel Blockers Heart Failure Therapeutics Product
Table 115. Calcium Channel Blockers Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 116. Calcium Channel Blockers Recent Development
Table 117. Cardiac Glycosides Company Detail
Table 118. Cardiac Glycosides Business Overview
Table 119. Cardiac Glycosides Heart Failure Therapeutics Product
Table 120. Cardiac Glycosides Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 121. Cardiac Glycosides Recent Development
Table 122. Diuretics Company Detail
Table 123. Diuretics Business Overview
Table 124. Diuretics Heart Failure Therapeutics Product
Table 125. Diuretics Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 126. Diuretics Recent Development
Table 127. Morphine Company Detail
Table 128. Morphine Business Overview
Table 129. Morphine Heart Failure Therapeutics Product
Table 130. Morphine Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 131. Morphine Recent Development
Table 132. Vasodilators/Nitrates Company Detail
Table 133. Vasodilators/Nitrates Business Overview
Table 134. Vasodilators/Nitrates Heart Failure Therapeutics Product
Table 135. Vasodilators/Nitrates Revenue in Heart Failure Therapeutics Business (2019-2024) & (US$ Million)
Table 136. Vasodilators/Nitrates Recent Development
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Heart Failure Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Heart Failure Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Diagnosis Features
Figure 4. Prognosis Features
Figure 5. Treatment Options and Treatment Algorithm Features
Figure 6. Global Heart Failure Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Heart Failure Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Medical Research Organization Case Studies
Figure 11. Heart Failure Therapeutics Report Years Considered
Figure 12. Global Heart Failure Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Heart Failure Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Heart Failure Therapeutics Market Share by Region: 2023 VS 2030
Figure 15. Global Heart Failure Therapeutics Market Share by Players in 2023
Figure 16. Global Top Heart Failure Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heart Failure Therapeutics as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Heart Failure Therapeutics Revenue in 2023
Figure 18. North America Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Heart Failure Therapeutics Market Share by Country (2019-2030)
Figure 20. United States Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Heart Failure Therapeutics Market Share by Country (2019-2030)
Figure 24. Germany Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Heart Failure Therapeutics Market Share by Region (2019-2030)
Figure 32. China Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Heart Failure Therapeutics Market Share by Country (2019-2030)
Figure 40. Mexico Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Heart Failure Therapeutics Market Share by Country (2019-2030)
Figure 44. Turkey Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Heart Failure Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Bayer Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 47. Cynokinetics Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 48. Les Laboratoires Servier Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 49. Merck & Co. Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 51. Procoralan Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 52. Bristol-Myers Squibb Company Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 53. Cardiorentis AG Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 54. CVie Therapeutics Limited Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 55. Orion Corporation Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 56. PhaseBio Pharmaceuticals Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 57. Market Segment by Product Type Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 58. B-Blockers Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 59. Calcium Channel Blockers Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 60. Cardiac Glycosides Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 61. Diuretics Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 62. Morphine Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 63. Vasodilators/Nitrates Revenue Growth Rate in Heart Failure Therapeutics Business (2019-2024)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
